Sorry, trader … Not too many low float dip and rips out there today.
Traditionally, that’s normal during earnings season. At least, it was before the market changed in 2020. But it kind of feels that way today.
A lot of huge companies have earnings coming up in the next few days, and a lot of people are in wait-and-see mode.
But don’t worry — there’s still plenty in play.
Here’s what I’m watching today…
All eyes on Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) … but I don’t like it. It popped and faded. It tried to pop again this morning. It might be my least favorite low-floater today. There’s gotta be something better than this!
I can admit it … I made the wrong call on Tyme Technologies Inc. (NASDAQ: TYME) yesterday. It ended up being a loser. I’m not above admitting when I make a blunder!
I also messed up by bashing Bit Digital Inc. (NASDAQ: BTBT) and Marathon Digital Holdings Inc. (NASDAQ: MARA) yesterday. They ended up performing well following bitcoin’s (BTC) big move on rumors related to Amazon.com, Inc. (NASDAQ: AMZN)...
A follower asked about Dynatronics Corp. (NASDAQ: DYNT) … This chart is a big fail. It’s got a long history of one-and-done moves. Bring something better to the table!
Oragenics Inc. (NYSEAMERICAN: OGEN) just issued a press release that’s all hopes and dreams. It’s got a ton of overhead resistance on the daily chart. But it’s a Scamex stock, and it had good volume in the premarket. It could be a dip and rip, especially if there’s a chat pump.
A follower asked about Exela Technologies Inc. (NASDAQ: XELA) … It’s got good news, but the chart is a mess. I’d say afternoon VWAP only.
I’ve been watching space-related play Orbsat Corp. (NASDAQ: OSAT) for some time now. It was gapping up this morning. It’s one to watch, but I couldn’t find a headline today...
Could it be a WallStreetBets pump? Without knowing the why, I can’t really make a call on this potential trade.
A follower asked about The9 Limited (NASDAQ: NCTY) over $14. Well, I’d say if you’re desperate to trade mediocre setups, this might be perfect for you.
As for my top watch? Probably Tesla Inc. (NASDAQ: TSLA) over $700. I did a 30-minute swing trade strategy session on TSLA with the SteadyTrade Team last night. Consider joining if you want deeper analysis...
🔴 Ready to learn more? Check out the SteadyTrade Team: https://stockstotrade.info/3x7S3fC
🔴 Try StocksToTrade for $7: https://stockstotrade.info/2UKTUdt
🔴 Check out Small Cap Rockets: https://stockstotrade.com/small-cap-rockets/
📲 Download the STT app for iOS: https://apps.apple.com/us/app/stockstotrade-mobile/id1403963724
📲 Download the STT app for Android: https://play.google.com/store/apps/details?id=com.stockstotrade
🔴 Subscribe for more free Stock Trading tips: YouTube.com/StocksToTrade
👉Share this video with a fellow Trader: https://youtu.be/obOY23dF-hE
✅ Links we mention and recommend:
🔴Try StocksToTrade for $7: https://stockstotrade.info/2UKTUdt
🔴Get our FREE weekly watchlist here: https://stockstotrade.info/3rChHbf
🔴Traders Blueprint Free Guide: https://stockstotrade.info/37ahBhz
🔴Check out the SteadyTrade Podcast: https://steadytrade.com
🔴FREE StocksToTrade Market Grind: https://lp.stockstotrade.com/market-grind/
✅ Recommended playlists:
🔴SteadyTrade Podcast: http://bit.ly/2SXbrv7
🔴Stock Trading 101: A Day Trader's Guide: http://bit.ly/2sqs1ZZ
🔴Advanced Stock Trading Tips: http://bit.ly/3a32pTM
🔴Trader Spotlight with Tim Bohen: http://bit.ly/36TTzG3
🔴StocksToTrade Software Tips and Tricks: http://bit.ly/375GSry
🔴Weekly Trading Recap Videos: http://bit.ly/3a32uXA
🔴Charts and Patterns: http://bit.ly/2uj2KBO
✅ Follow StocksToTrade on social media:
Instagram: https://www.instagram.com/stockstotrade/
Facebook: https://www.facebook.com/StocksToTrade/
Twitter: https://twitter.com/StocksToTrade
#StockMarket #Stocks #PreMarket
*Tim Bohen teaches skills others have used to make money. Most who receive free or paid content will make little or no money because they will not apply the skills being taught. Any results displayed may be exceptional. We do not guarantee any outcome regarding your earnings or income as the factors that impact such results are numerous and uncontrollable.
You can lose money trading stocks. Do not invest money you cannot afford to lose. You understand and agree you will consider the important risk factors in deciding to purchase any of our products or services.
Traditionally, that’s normal during earnings season. At least, it was before the market changed in 2020. But it kind of feels that way today.
A lot of huge companies have earnings coming up in the next few days, and a lot of people are in wait-and-see mode.
But don’t worry — there’s still plenty in play.
Here’s what I’m watching today…
All eyes on Eyegate Pharmaceuticals Inc. (NASDAQ: EYEG) … but I don’t like it. It popped and faded. It tried to pop again this morning. It might be my least favorite low-floater today. There’s gotta be something better than this!
I can admit it … I made the wrong call on Tyme Technologies Inc. (NASDAQ: TYME) yesterday. It ended up being a loser. I’m not above admitting when I make a blunder!
I also messed up by bashing Bit Digital Inc. (NASDAQ: BTBT) and Marathon Digital Holdings Inc. (NASDAQ: MARA) yesterday. They ended up performing well following bitcoin’s (BTC) big move on rumors related to Amazon.com, Inc. (NASDAQ: AMZN)...
A follower asked about Dynatronics Corp. (NASDAQ: DYNT) … This chart is a big fail. It’s got a long history of one-and-done moves. Bring something better to the table!
Oragenics Inc. (NYSEAMERICAN: OGEN) just issued a press release that’s all hopes and dreams. It’s got a ton of overhead resistance on the daily chart. But it’s a Scamex stock, and it had good volume in the premarket. It could be a dip and rip, especially if there’s a chat pump.
A follower asked about Exela Technologies Inc. (NASDAQ: XELA) … It’s got good news, but the chart is a mess. I’d say afternoon VWAP only.
I’ve been watching space-related play Orbsat Corp. (NASDAQ: OSAT) for some time now. It was gapping up this morning. It’s one to watch, but I couldn’t find a headline today...
Could it be a WallStreetBets pump? Without knowing the why, I can’t really make a call on this potential trade.
A follower asked about The9 Limited (NASDAQ: NCTY) over $14. Well, I’d say if you’re desperate to trade mediocre setups, this might be perfect for you.
As for my top watch? Probably Tesla Inc. (NASDAQ: TSLA) over $700. I did a 30-minute swing trade strategy session on TSLA with the SteadyTrade Team last night. Consider joining if you want deeper analysis...
🔴 Ready to learn more? Check out the SteadyTrade Team: https://stockstotrade.info/3x7S3fC
🔴 Try StocksToTrade for $7: https://stockstotrade.info/2UKTUdt
🔴 Check out Small Cap Rockets: https://stockstotrade.com/small-cap-rockets/
📲 Download the STT app for iOS: https://apps.apple.com/us/app/stockstotrade-mobile/id1403963724
📲 Download the STT app for Android: https://play.google.com/store/apps/details?id=com.stockstotrade
🔴 Subscribe for more free Stock Trading tips: YouTube.com/StocksToTrade
👉Share this video with a fellow Trader: https://youtu.be/obOY23dF-hE
✅ Links we mention and recommend:
🔴Try StocksToTrade for $7: https://stockstotrade.info/2UKTUdt
🔴Get our FREE weekly watchlist here: https://stockstotrade.info/3rChHbf
🔴Traders Blueprint Free Guide: https://stockstotrade.info/37ahBhz
🔴Check out the SteadyTrade Podcast: https://steadytrade.com
🔴FREE StocksToTrade Market Grind: https://lp.stockstotrade.com/market-grind/
✅ Recommended playlists:
🔴SteadyTrade Podcast: http://bit.ly/2SXbrv7
🔴Stock Trading 101: A Day Trader's Guide: http://bit.ly/2sqs1ZZ
🔴Advanced Stock Trading Tips: http://bit.ly/3a32pTM
🔴Trader Spotlight with Tim Bohen: http://bit.ly/36TTzG3
🔴StocksToTrade Software Tips and Tricks: http://bit.ly/375GSry
🔴Weekly Trading Recap Videos: http://bit.ly/3a32uXA
🔴Charts and Patterns: http://bit.ly/2uj2KBO
✅ Follow StocksToTrade on social media:
Instagram: https://www.instagram.com/stockstotrade/
Facebook: https://www.facebook.com/StocksToTrade/
Twitter: https://twitter.com/StocksToTrade
#StockMarket #Stocks #PreMarket
*Tim Bohen teaches skills others have used to make money. Most who receive free or paid content will make little or no money because they will not apply the skills being taught. Any results displayed may be exceptional. We do not guarantee any outcome regarding your earnings or income as the factors that impact such results are numerous and uncontrollable.
You can lose money trading stocks. Do not invest money you cannot afford to lose. You understand and agree you will consider the important risk factors in deciding to purchase any of our products or services.
Agenus Inc. (AGEN) PT Raised to $11 at B.RILEY
Current stock price is $4.90
Agenus (ticker symbol AGEN) is an immuno-therapy clinical stage company. They also produce vaccines and cell therapy (INKT’S) through their subsidiary company Agentus.
Their main product and near future revenue generators are their PD-1 and CTLA-4 CPMS. The FDA just recently accepted priority review for the BLA filing of AGEN2034, their PD-1 molecule in second line cervical cancer. They have a PDUFA date set for December 16, 2021. They’re also on track for a BLA filing with their PD-1 and first generation CTLA-4 in combination for the same indication. Agenus’s PD-1 has shown clinical proof to be differentiated from the other PD-1’s that are already out there on the market; mainly it’s superiority over keytruda (in second line CC). More importantly, Agenus’s PD-1 works in both PD-L1 positive AND negative tumors. Keytruda’s does not.
Agenus also has the most powerful adjuvant (QS-21 stimulon) on the market. Not to be confused with the other QS-21’s that are out there. QS-21 stimulon is basically an ingredient that increases the efficacy of a vaccine/drug (COVID-19?) QS-21 stimulon is one of the main reasons why GSK’s shingrix vaccine has taken up most of the market share. Agenus is currently working on getting funding from the government to rapidly increase production.
Agenus is partnered with Incyte, Merck, Gilead, Glaxosmithkline and most recently, Bristol Myers Squibb. Agenus set a previous record for money given for three preclinical molecules with Gilead for ~150m upfront cash (30m in equity) along with future potential royalties and milestones worth around ~1.7B. However this year, BMY beat that figure by acquiring only one preclinical molecule which is a TIGIT BISPECIFIC to the tune of ~200m along with future potential milestones and royalties worth ~1.36B
However, the most exciting molecule they have could be a potential multi blockbuster which is their next generation CTLA-4 AGEN1181. This is what most investors are banking on. It’s currently in phase 2. It was generating partial and complete responses in phase 1 which is very promising ‘cause phase 1 is administered in low dosage to monitor toxicity levels and showing very promising results. Ctla-4 is notorious for being toxic but agenus has manufactured a version that has sustained tolerable toxicity levels. This is huge. They will be presenting data at the next big venue which will either be at ESMO in September or SITC in December.
They have a vast pipeline for such a small company. Probably the most robust pipeline out of any company their size.
Finally, they have a clinical trial with their INKT cell therapy that’s showing positive signs in patients with severe symptoms from COVID-19. So far, 3 out of 4 patients have been extubated (taken off ventilators) within 24 hours. These trials have been running a little slow but they’re expecting additional clinical data soon. However, COVID-19 is not their primary objective with INKT’s. It was nearly an afterthought during the pandemic. Their INKT’s will mainly target Cancer cells.
Final note: institutions have recently taken more of an interest in Agenus. I believe institutional holdings have increased by over 10 percent. Agenus has about ~319m in cash as of last quarter which would give them about roughly 2 years of cash runway. GLTALS
Thank you for the great education
I was watching TYME, no play for me. I make mistakes too, we all do. I played XBIO close to the bell, didn't wait.